High baseline plasma myeloperoxidase (≥1,150 ng/ml) was an independent predictor of 30-day major adverse clinical events in ST-segment elevation AMI patients undergoing primary PCI (P<0.0001).
Observational (n=128)
Does baseline plasma myeloperoxidase (MPO) level predict 30-day MACE in patients with ST-segment elevation AMI undergoing primary PCI?
High baseline plasma myeloperoxidase (MPO) level is a strong independent predictor of 30-day major adverse clinical events in patients with ST-segment elevation AMI undergoing primary PCI.
p-value: p=<0.0001
BACKGROUND: This study tested the hypothesis that the baseline plasma level of myeloperoxidase (MPO) independently predicts risk of patients with ST-segment elevation (ST-se) acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: Plasma MPO levels in 128 patients were examined by ELISA. They were significantly higher in AMI patients than in normal controls (Por=1,150 ng/ml) had significantly higher white blood cell counts, a higher plasma level of oxidized low-density lipoprotein, higher peak MB fraction of creatine kinase level, significantly lower left ventricular ejection fraction, and significantly higher incidence of 30-day composite major adverse clinical events (MACE) (defined as Killip score>or=3, re-infarction, repeat PCI, or 30-day mortality) than those patients with low plasma MPO level (or=1,150 pg/ml) was the most independent predictor of 30-day MACE (P<0.0001). CONCLUSIONS: Plasma MPO level is a major independent inflammatory predictor of 30-day MACE in ST-se AMI patients. Evaluation of the circulating MPO level might improve the prediction of unfavorable clinical outcome following AMI.
Chang et al. (Thu,) conducted a observational in ST-segment elevation acute myocardial infarction (AMI) (n=128). High plasma myeloperoxidase (MPO) level (≥1,150 ng/ml) vs. Low plasma MPO level (<1,150 ng/ml) was evaluated on 30-day composite major adverse clinical events (MACE) (Killip score≥3, re-infarction, repeat PCI, or 30-day mortality) (p=<0.0001). High baseline plasma myeloperoxidase (≥1,150 ng/ml) was an independent predictor of 30-day major adverse clinical events in ST-segment elevation AMI patients undergoing primary PCI (P<0.0001).